NCT05985863View on ClinicalTrials.gov

Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 30, 2023

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2028

Conditions
Acute-On-Chronic Liver Failure
Interventions
DRUG

standard medical treatment

standard medical treatment for ACLF

DRUG

Placebo

5% human serum albumin in 0.9% saline (at week0, week1 and week2)

DRUG

hUC-MSC

hUC-MSC (1.5×10\^8 cells/time, Peripheral IV, at week0, week1 and week2)

DRUG

hUC-MSC_Prolonged

hUC-MSC (1.5×10\^8 cells/time, Peripheral IV, at week4 and week5)

Trial Locations (1)

100039

RECRUITING

the Fifth Medical Center, Chinese PLA General Hospital, Beijing

All Listed Sponsors
collaborator

Shulan (Hang Zhou) Hospital

UNKNOWN

collaborator

BeijingYouan Hospital

UNKNOWN

collaborator

Shenzhen Third People's Hospital

OTHER

collaborator

Shen Zhen Wingor Biotechnology CO. LTD

INDUSTRY

lead

Beijing 302 Hospital

OTHER